Industry Gets Say At DIA As New China Drug Law In The Works
This article was originally published in PharmAsia News
Executive Summary
A marketing authorization holder system, faster and strict timeframes for investigative new drug approval, and stricter monitoring of off-label drug use were the top topics at a special discussion of China’s top regulators, legal experts and industry executives.